Breast Atypia as a Biomarker of Risk

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Purpose of Review: Provide a summary of available evidence on breast atypia as a biomarker of risk. Recent Findings: With an increase in independent studies on atypical hyperplasia (AH), knowledge has advanced recently regarding its subsequent associated breast cancer risk. For women with AH, absolute risk can be estimated generally as ~ 1% per year, and a greater extent of disease appears to further increase risk. Although both breasts are at increased risk, the risk is higher for the ipsilateral breast. In women with AH, a family history of breast cancer does not confer significantly increased risk. Risk is similar for atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), with some reports suggesting mildly higher risk for ALH. Prevention medications reduce breast cancer risk by ~ 70% in AH. Summary: Women with AH should be counseled on their increased risk and the option of prevention medication.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalCurrent Breast Cancer Reports
Issue number3
StatePublished - Sep 15 2019


  • Atypical hyperplasia
  • Biomarker
  • Breast
  • Breast cancer
  • Risk
  • Risk prediction

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Breast Atypia as a Biomarker of Risk'. Together they form a unique fingerprint.

Cite this